162 related articles for article (PubMed ID: 8674073)
1. Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells.
Sleeman JP; Arming S; Moll JF; Hekele A; Rudy W; Sherman LS; Kreil G; Ponta H; Herrlich P
Cancer Res; 1996 Jul; 56(13):3134-41. PubMed ID: 8674073
[TBL] [Abstract][Full Text] [Related]
2. Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate.
Gao AC; Lou W; Sleeman JP; Isaacs JT
Cancer Res; 1998 Jun; 58(11):2350-2. PubMed ID: 9622073
[TBL] [Abstract][Full Text] [Related]
3. Regulation of human CD44H and CD44E isoform binding to hyaluronan by phorbol myristate acetate and anti-CD44 monoclonal and polyclonal antibodies.
Liao HX; Levesque MC; Patton K; Bergamo B; Jones D; Moody MA; Telen MJ; Haynes BF
J Immunol; 1993 Dec; 151(11):6490-9. PubMed ID: 7504022
[TBL] [Abstract][Full Text] [Related]
4. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment.
Reeder JA; Gotley DC; Walsh MD; Fawcett J; Antalis TM
Cancer Res; 1998 Aug; 58(16):3719-26. PubMed ID: 9721884
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells.
Abetamann V; Kern HF; Elsässer HP
Clin Cancer Res; 1996 Sep; 2(9):1607-18. PubMed ID: 9816340
[TBL] [Abstract][Full Text] [Related]
6. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells.
Welsh CF; Zhu D; Bourguignon LY
J Cell Physiol; 1995 Sep; 164(3):605-12. PubMed ID: 7544357
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid.
Ahrens T; Sleeman JP; Schempp CM; Howells N; Hofmann M; Ponta H; Herrlich P; Simon JC
Oncogene; 2001 Jun; 20(26):3399-408. PubMed ID: 11423990
[TBL] [Abstract][Full Text] [Related]
8. A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells.
Hofmann M; Rudy W; Günthert U; Zimmer SG; Zawadzki V; Zöller M; Lichtner RB; Herrlich P; Ponta H
Cancer Res; 1993 Apr; 53(7):1516-21. PubMed ID: 8453616
[TBL] [Abstract][Full Text] [Related]
9. N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding.
Liao HX; Lee DM; Levesque MC; Haynes BF
J Immunol; 1995 Oct; 155(8):3938-45. PubMed ID: 7561101
[TBL] [Abstract][Full Text] [Related]
10. CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas.
Takahashi K; Stamenkovic I; Cutler M; Saya H; Tanabe KK
Oncogene; 1995 Dec; 11(11):2223-32. PubMed ID: 8570172
[TBL] [Abstract][Full Text] [Related]
11. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance.
Klingbeil P; Marhaba R; Jung T; Kirmse R; Ludwig T; Zöller M
Mol Cancer Res; 2009 Feb; 7(2):168-79. PubMed ID: 19208744
[TBL] [Abstract][Full Text] [Related]
12. Site-specific de-N-glycosylation of CD44 can activate hyaluronan binding, and CD44 activation states show distinct threshold densities for hyaluronan binding.
English NM; Lesley JF; Hyman R
Cancer Res; 1998 Aug; 58(16):3736-42. PubMed ID: 9721887
[TBL] [Abstract][Full Text] [Related]
13. The CD44 receptor of the mouse LB T-cell lymphoma: analysis of the isoform repertoire and ligand binding properties by reverse-transcriptase polymerase chain reaction and antisense oligonucleotides.
Wallach SB; Friedmann A; Naor D
Cancer Detect Prev; 2000; 24(1):33-45. PubMed ID: 10757121
[TBL] [Abstract][Full Text] [Related]
14. CD44 can be activated to function as an hyaluronic acid receptor in normal murine T cells.
Lesley J; Hyman R
Eur J Immunol; 1992 Oct; 22(10):2719-23. PubMed ID: 1382996
[TBL] [Abstract][Full Text] [Related]
15. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior.
Rudy W; Hofmann M; Schwartz-Albiez R; Zöller M; Heider KH; Ponta H; Herrlich P
Cancer Res; 1993 Mar; 53(6):1262-8. PubMed ID: 8443806
[TBL] [Abstract][Full Text] [Related]
16. Requirements for signal delivery through CD44: analysis using CD44-Fas chimeric proteins.
Ishiwatari-Hayasaka H; Fujimoto T; Osawa T; Hirama T; Toyama-Sorimachi N; Miyasaka M
J Immunol; 1999 Aug; 163(3):1258-64. PubMed ID: 10415022
[TBL] [Abstract][Full Text] [Related]
17. Absence of functional CD44 hyaluronan receptor on human NMYC-amplified neuroblastoma cells.
Gross N; Balmas K; Brognara CB
Cancer Res; 1997 Apr; 57(7):1387-93. PubMed ID: 9102228
[TBL] [Abstract][Full Text] [Related]
18. CD44 expression on activated B cells. Differential capacity for CD44-dependent binding to hyaluronic acid.
Hathcock KS; Hirano H; Murakami S; Hodes RJ
J Immunol; 1993 Dec; 151(12):6712-22. PubMed ID: 7505013
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44.
Golshani R; Lopez L; Estrella V; Kramer M; Iida N; Lokeshwar VB
Cancer Res; 2008 Jan; 68(2):483-91. PubMed ID: 18199543
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44.
Kim HR; Wheeler MA; Wilson CM; Iida J; Eng D; Simpson MA; McCarthy JB; Bullard KM
Cancer Res; 2004 Jul; 64(13):4569-76. PubMed ID: 15231668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
